Erlotinib News and Research

RSS

Erlotinib is a drug used to treat certain types of non-small cell lung cancer. It is also used together with gemcitabine to treat pancreatic cancer and is being studied in the treatment of other types of cancer. Erlotinib is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Also called CP-358,774, erlotinib hydrochloride, OSI-774, and Tarceva.

Focusing on oncogenic driver mutations and resistance mechanisms in the treatment of NSCLC

Lung cancer is the leading cause of cancer-related death worldwide. Improved understanding of driver mutations of non-small cell lung cancer (NSCLC) has led to more biomarker-directed treatment for patients with advanced stages.

26 Mar 2024

Effect of mutations in cancer-driving genes across human cancers

Effect of mutations in cancer-driving genes across human cancers.

9 Aug 2023

New $5.3 million NIH grant will support researchers into understanding lung cancer recurrence

Researchers at Washington University School of Medicine in St. Louis are leading a national study aimed at identifying patients with early-stage lung cancer who are at high risk of having the cancer return, even after surgery and chemotherapy appear to have eliminated their tumors.

28 Jun 2022

MAPK pathway mutations can provide “precision” treatment targets for head and neck cancer

About one-fifth of often deadly head and neck cancers harbor genetic mutations in a pathway that is key to normal cell growth, and scientists report those mutations, which enable abnormal cancer cell growth, can also make the cancer vulnerable.

28 Apr 2022

New cellular pathway limits growth and spread of brain tumors

Researchers at McGill University have identified a new cellular pathway that limits the growth and spread of brain tumors by controlling the recycling of cell surface receptor proteins.

14 Jan 2021

New therapeutic strategy for lung cancer and associated secondary tumors

In 20 - 40% of patients with cancer, metastasis (the development of secondary tumors) in the central nervous system (CNS) occurs. CNS metastatis impacts negatively on a patient's quality of life, and is associated with a poor health prognosis.

8 Feb 2020

Researchers discover new chemical weapon to fight against cancer

The fight against cancer involves eradicating cancer cells but current treatments inevitably have negative consequences on healthy cells.

23 Oct 2019

UC San Diego researchers identify new therapeutic approach to kill cancer cells

Epithelial cancers, such as cancers of the lung and pancreas, use the ανβ3 molecule to gain drug resistance to standard cancer therapies and to become highly metastatic.

22 Aug 2019

Dacomitinib treatment for lung cancer increases overall survival but has more side effects

Since its approval in April 2019, dacomitinib has been available for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor activating mutations.

20 Aug 2019

New cell co-culture platform holds promise for future of personalized medicine

Why doesn't the same treatment work in the same way for every patient?

22 May 2019

Tobacco use causes precancerous cells to 'fertilize' nearby cells with cancerous changes

Tobacco use causes a field of precancerous cells, increasing the risk of developing head & neck cancer. But exactly how this precancerous field influences cancer has been often overlooked.

2 Apr 2019

Blood-based liquid biopsies can accurately track cancer treatment responses

Results of two clinical studies have added to evidence that blood-based liquid biopsies can accurately track lung cancer treatment responses by measuring circulating tumor DNA (ctDNA) during immunotherapy and related treatments.

14 Feb 2019

Physicians more likely to prescribe drugs of manufacturers who paid them money

In a study published in The Oncologist, physicians treating certain cancers who consistently received payments from a cancer drug's manufacturer were more likely to prescribe that drug over alternative treatments.

6 Feb 2019

Toxic effects of drugs in the lungs 'more widespread than thought'

A systematic review of research has revealed that the toxic effects on the lung of drugs commonly taken to treat a range of common conditions is much more widespread than thought.

29 Oct 2018

Raman microscopy can help detect cancer drug resistance

Biophysicists at Ruhr-Universität Bochum have demonstrated that Raman microscopy can be used to detect the resistance of tumor cells to cancer drugs.

26 Oct 2018

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Neoadjuvant erlotinib benefits selected epidermal growth factor receptor (EGFR)-mutated patients who undergo complete resection of stage IIIA-N2 stage non-small cell lung cancer(NSCLC), shows a randomized study comparing erlotinib with gemcitabine plus cisplatin as neoadjuvant treatment, presented at the ESMO 2018 Congress in Munich.

22 Oct 2018

Scientists uncover new way to make cancers sensitive to treatment

Scientists have uncovered a completely new way to make cancers sensitive to treatment - by targeting antenna-like structures on cells.

6 Jun 2018

Osimertinib provides progression-free survival benefit to Asian patients with EGFR-mutated NSCLC

Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset analysis of the FLAURA trial presented at the ESMO Asia 2017 Congress, sumultaneously published in The New England Journal of Medicine.

20 Nov 2017

Researchers use gold nanoshells to effectively release cancer drugs inside tumors

Researchers investigating ways to deliver high doses of cancer-killing drugs inside tumors have shown they can use a laser and light-activated gold nanoparticles to remotely trigger the release of approved cancer drugs inside cancer cells in laboratory cultures.

8 Nov 2017

New study finds enhanced impact of drug combination for FAP patients

People with an inherited syndrome called familial adenomatous polyposis (FAP) have a 100% lifetime risk of developing colorectal cancer if they do not seek appropriate medical care.

7 Nov 2017